{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T03:12:16Z","timestamp":1761621136130},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.lpm.2013.01.066","type":"journal-article","created":{"date-parts":[[2013,5,28]],"date-time":"2013-05-28T00:00:21Z","timestamp":1369699221000},"page":"1461-1468","source":"Crossref","is-referenced-by-count":6,"title":["Progr\u00e8s r\u00e9cents dans les th\u00e9rapies cibl\u00e9es dans le traitement du cancer du sein m\u00e9tastatique HER2-positif"],"prefix":"10.1016","volume":"42","author":[{"given":"Nabil","family":"Ismaili","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhizlane","family":"Belbaraka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelhamid","family":"Elomrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouna","family":"Khouchani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Tahri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2013.01.066_bib0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-4757-3147-7_4","article-title":"The molecular and cellular biology of HER2\/neu gene amplification\/overexpression and the clinical development of Herceptin (trastuzumab) therapy for breast cancer","volume":"103","author":"Pegram","year":"2000","journal-title":"Cancer Treat Res"},{"issue":"1\u00a0Suppl.\u00a01","key":"10.1016\/j.lpm.2013.01.066_bib0010","first-page":"S53","article-title":"HER-2\/neu (c-erb-B2) gene and protein in breast cancer","volume":"112","author":"Ross","year":"1999","journal-title":"Am J Clin Pathol"},{"issue":"4785","key":"10.1016\/j.lpm.2013.01.066_bib0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"issue":"4905","key":"10.1016\/j.lpm.2013.01.066_bib0020","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.lpm.2013.01.066_bib0025","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMp058197","article-title":"The distinctive nature of HER2-positive breast cancers","volume":"353","author":"Burstein","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lpm.2013.01.066_bib0030","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.lpm.2013.01.066_bib0035","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2\u00a0for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2013.01.066_bib0040","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2\u2013positive metastatic breast cancer administered as first-line treatment: The M77001\u00a0Study Group","volume":"23","author":"Marty","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.lpm.2013.01.066_bib0045","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10549-006-9306-9","article-title":"Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2\u00a0positive advanced breast cancer","volume":"101","author":"Gasparini","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.lpm.2013.01.066_bib0050","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cncr.22885","article-title":"Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study","volume":"110","author":"Burstein","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.lpm.2013.01.066_bib0055","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.2007.11.9776","article-title":"Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer","volume":"25","author":"Bartsch","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.lpm.2013.01.066_bib0060","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JCO.2010.28.6450","volume":"29","author":"Valero","year":"2011","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.lpm.2013.01.066_bib0065","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1200\/JCO.2008.20.6847","article-title":"Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study","volume":"27","author":"Kaufman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.lpm.2013.01.066_bib0070","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1200\/JCO.2007.14.0590","article-title":"Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer","volume":"26","author":"Gomez","year":"2008","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.lpm.2013.01.066_bib0075","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","article-title":"Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer","volume":"27","author":"Johnston","year":"2009","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.lpm.2013.01.066_bib0080","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.lpm.2013.01.066_bib0085","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1634\/theoncologist.2009-0181","article-title":"Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial","volume":"15","author":"Cameron","year":"2010","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.lpm.2013.01.066_bib0090","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10549-007-9885-0","article-title":"A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses","volume":"112","author":"Cameron","year":"2008","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.lpm.2013.01.066_bib0095","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/onc.2008.432","article-title":"Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity","volume":"28","author":"Scaltriti","year":"2009","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.lpm.2013.01.066_bib0100","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1158\/0008-5472.CAN-05-1182","article-title":"Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells","volume":"66","author":"Konecny","year":"2006","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.lpm.2013.01.066_bib0105","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.onc.1207166","article-title":"Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR\/ErbB2 kinase inhibitor GW572016","volume":"23","author":"Xia","year":"2004","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.lpm.2013.01.066_bib0110","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.lpm.2013.01.066_bib0115","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2008.19.6618","article-title":"Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26\/breast international group 03-05\u00a0study","volume":"27","author":"von Minckwitz","year":"2009","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.lpm.2013.01.066_bib0120","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2009.26.2071","article-title":"Phase I study of trastuzumab-DM1, an HER2\u00a0antibody-drug conjugate, given every 3\u00a0weeks to patients with HER2-positive metastatic breast cancer","volume":"28","author":"Krop","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2013.01.066_bib0125","unstructured":"Holden SN, et al. ASCO 2008. Abstract 1029."},{"key":"10.1016\/j.lpm.2013.01.066_bib0130","unstructured":"Emilia. ASCO 2012; ClinicalTrials.gov. NCT00829166."},{"key":"10.1016\/j.lpm.2013.01.066_bib0135","unstructured":"Perez EA, et al. ESMO 2010. Abstract LBA3."},{"key":"10.1016\/j.lpm.2013.01.066_bib0140","unstructured":"ClinicalTrials.gov. NCT01120184."},{"issue":"4","key":"10.1016\/j.lpm.2013.01.066_bib0145","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ccr.2005.04.004","article-title":"EGF receptor inhibition: attacks on multiple fronts","volume":"7","author":"Hubbard","year":"2005","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.lpm.2013.01.066_bib0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.lpm.2013.01.066_bib0155","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2174\/187152008784533062","article-title":"HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?","volume":"8","author":"Widakowich","year":"2008","journal-title":"Anticancer Agents Med Chem"},{"issue":"23","key":"10.1016\/j.lpm.2013.01.066_bib0160","doi-asserted-by":"crossref","first-page":"7266","DOI":"10.1158\/1078-0432.CCR-09-1665","article-title":"Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2\u00a0inhibitors against HER2-overexpressing cancer cells","volume":"15","author":"Miller","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"34","key":"10.1016\/j.lpm.2013.01.066_bib0165","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1200\/JCO.2009.27.8549","article-title":"Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab","volume":"28","author":"Andre","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2013.01.066_bib0170","unstructured":"BOLERO-1\u00a0ClinicalTrials.gov. NCT00876395."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.lpm.2013.01.066_bib0175","first-page":"S124","article-title":"Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF)","volume":"88","author":"Pegram","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.lpm.2013.01.066_bib0180","unstructured":"Pegram MD, et al. SABCS 2006. Abstract 301."},{"key":"10.1016\/j.lpm.2013.01.066_bib0185","unstructured":"BETH. Treatment of HER2\u00a0positive breast cancer with chemotherapy plus trastuzumab vs chemotherapy plus trastuzumab plus bevacizumab (December 2010). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00625898."},{"key":"10.1016\/j.lpm.2013.01.066_bib0190","unstructured":"AVEREL. A study of bevacizumab in combination with trastuzumab\/docetaxel in patients with HER2\u00a0positive metastatic breast cancer (May 2011). http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00391092."},{"issue":"1","key":"10.1016\/j.lpm.2013.01.066_bib0195","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","article-title":"Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review","volume":"28","author":"Dawood","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498213005630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498213005630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T19:23:10Z","timestamp":1539631390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498213005630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0755498213005630"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2013.01.066","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}